No data available for drug.
Dosing & Uses
Drug Interaction
Adverse Reaction
Actions and Spectrum
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Administration
Patient Information Leaflet
DRUG INTERACTION
No drug interaction found for peginterferon alfa-2b and .
Contraindicated
tirofiban
may increase the serum concentration of each other when combined
rimantadine
may decrease the therapeutic effect of each other when combined
lenograstim
may decrease the therapeutic effect when combined with lenograstim
lipegfilgrastim
may diminish the therapeutic effect when combined with lipegfilgrastim
palifermin
may increase the adverse effect when combined with antineoplastic agents
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
curcumin
may increase the levels of serum concentration
glecaprevir
may increase the levels of serum concentration
caspofungin
may increase the levels of serum concentration
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
diacerein
may increase the levels of serum concentration
abiraterone
may enhance the serum concentration of each other when combined
mibefradil
may enhance the serum concentration of each other when combined
diacerein
may enhance the serum concentration of each other when combined
tranylcypromine
may enhance the serum concentration of each other when combined
anastrozole
may enhance the serum concentration of each other when combined
primidone
may increase the serum concentration of each other when combined
phenobarbital
may increase the serum concentration of each other when combined
isoniazid
may increase the serum concentration of each other when combined
prednisolone
may increase the serum concentration of each other when combined
propofol
may increase the serum concentration of each other when combined
Serious Use Alternative
Monitor Closely
pioglitazone
may enhance the hypoglycemic effect of antidiabetic agents
acarbose
may enhance the hypoglycemic effect of antidiabetic agents
glymidine
may enhance the hypoglycemic effect of antidiabetic agents
repaglinide
may enhance the hypoglycemic effect of antidiabetic agents
pegloticase
It may diminish the therapeutic efficacy when combined with pegloticase
lenacapavir
it may increase the levels of serum concentration
abiraterone
it may increase the levels of serum concentration
mibefradil
it may increase the levels of serum concentration
citalopram
it may increase the levels of serum concentration
efavirenz
it may increase the levels of serum concentration
tirzepatide
antiviral agents (HCV): they may increase the hypoglycemic effect of antidiabetic drugs
tolbutamide
may increase the hypoglycemic effect of Antidiabetic Agents
bleomycin
it enhance the risk of pulmonary toxicity
bempedoic acid
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
caspofungin
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
darolutamide
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
clarithromycin
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
lonafarnib
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
ertugliflozin
may increase the Glucose-lowering effect of Antidiabetic Agents
Minor
No data available for drug.
Dosing & Uses
Adult
Pediatric
Geriatric
Drug Interaction
DRUG INTERACTION
peginterferon alfa-2b
&
No Drug Intearction Found. for peginterferon alfa-2b and .
Contraindicated
tirofiban
may increase the serum concentration of each other when combined
rimantadine
may decrease the therapeutic effect of each other when combined
lenograstim
may decrease the therapeutic effect when combined with lenograstim
lipegfilgrastim
may diminish the therapeutic effect when combined with lipegfilgrastim
palifermin
may increase the adverse effect when combined with antineoplastic agents
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
curcumin
may increase the levels of serum concentration
glecaprevir
may increase the levels of serum concentration
caspofungin
may increase the levels of serum concentration
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
diacerein
may increase the levels of serum concentration
abiraterone
may enhance the serum concentration of each other when combined
mibefradil
may enhance the serum concentration of each other when combined
diacerein
may enhance the serum concentration of each other when combined
tranylcypromine
may enhance the serum concentration of each other when combined
anastrozole
may enhance the serum concentration of each other when combined
primidone
may increase the serum concentration of each other when combined
phenobarbital
may increase the serum concentration of each other when combined
isoniazid
may increase the serum concentration of each other when combined
prednisolone
may increase the serum concentration of each other when combined
propofol
may increase the serum concentration of each other when combined
Serious Use Alternative
Monitor Closely
pioglitazone
may enhance the hypoglycemic effect of antidiabetic agents
acarbose
may enhance the hypoglycemic effect of antidiabetic agents
glymidine
may enhance the hypoglycemic effect of antidiabetic agents
repaglinide
may enhance the hypoglycemic effect of antidiabetic agents
pegloticase
It may diminish the therapeutic efficacy when combined with pegloticase
lenacapavir
it may increase the levels of serum concentration
abiraterone
it may increase the levels of serum concentration
mibefradil
it may increase the levels of serum concentration
citalopram
it may increase the levels of serum concentration
efavirenz
it may increase the levels of serum concentration
tirzepatide
antiviral agents (HCV): they may increase the hypoglycemic effect of antidiabetic drugs
tolbutamide
may increase the hypoglycemic effect of Antidiabetic Agents
bleomycin
it enhance the risk of pulmonary toxicity
bempedoic acid
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
caspofungin
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
darolutamide
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
clarithromycin
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
lonafarnib
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
ertugliflozin
may increase the Glucose-lowering effect of Antidiabetic Agents
Minor
Actions and Spectrum
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Administration
Patient Information Leaflet
medtigo
Action and Spectrum
Drug Interaction
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Adminstartion
Patient Information Leaflet